Banco Bilbao Vizcaya Argentaria S.A. Raises Position in Amgen Inc. $AMGN

Banco Bilbao Vizcaya Argentaria S.A. grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 93.2% during the fourth quarter, HoldingsChannel reports. The firm owned 162,989 shares of the medical research company’s stock after purchasing an additional 78,626 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in Amgen were worth $53,357,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in AMGN. Robeco Institutional Asset Management B.V. increased its holdings in shares of Amgen by 10.0% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock worth $157,584,000 after buying an additional 43,884 shares during the last quarter. Curtis Advisory Group LLC acquired a new stake in shares of Amgen during the 4th quarter worth $1,669,000. Adell Harriman & Carpenter Inc. increased its holdings in shares of Amgen by 7.9% during the 4th quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock worth $7,204,000 after buying an additional 1,609 shares during the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new stake in shares of Amgen during the 4th quarter worth $22,441,000. Finally, Sigma Planning Corp increased its holdings in shares of Amgen by 24.0% during the 4th quarter. Sigma Planning Corp now owns 17,992 shares of the medical research company’s stock worth $5,889,000 after buying an additional 3,488 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

NASDAQ:AMGN opened at $341.66 on Thursday. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. The firm has a 50-day moving average of $341.01 and a two-hundred day moving average of $345.86. The stock has a market cap of $184.40 billion, a P/E ratio of 23.78, a PEG ratio of 3.49 and a beta of 0.42. Amgen Inc. has a 1-year low of $267.83 and a 1-year high of $391.29.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. The company had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the prior year, the company posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, research analysts expect that Amgen Inc. will post 22.38 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on AMGN shares. Guggenheim lowered their price target on Amgen from $351.00 to $340.00 and set a “neutral” rating for the company in a report on Monday, May 4th. Barclays started coverage on Amgen in a report on Friday, February 20th. They issued an “equal weight” rating and a $350.00 price target for the company. Truist Financial increased their price target on Amgen from $325.00 to $327.00 and gave the company a “hold” rating in a report on Friday, May 1st. Erste Group Bank reiterated a “hold” rating on shares of Amgen in a report on Tuesday, May 5th. Finally, Daiwa Securities Group lowered their price target on Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a report on Wednesday, May 13th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, fifteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $354.42.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This represents a 15.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.85% of the stock is currently owned by insiders.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.